Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intensive Treatment to Reach the Target with Golimumab in Ulcerative Colitis (In-TARGET)
2016-000152-96Phase 4Completed
- Sponsor
- GETAID
- Start
- Nov 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, single-arm trial of golimumab in autoimmune colitis, sponsored by GETAID. Primary endpoints: Continuous Clinical Response and Mucosal Healing at Week 54 and CCR with Mucosal Healing at Week 108 after De-escalation/Discontinuation. Started Nov 2019; status: completed.
02
Drugs
golimumab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2016-000152-96.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000152-96.